| Product | Indication | Dosage form | Strength |
|---|---|---|---|
| Piracetam | Alzheimer | Oral solution | 333 mg/ml |
| Piracetam | Alzheimer | Solution for injection | 200mg/ ml |
| Pramipexol | Parkinson's | IR tablets | 0.088, 0.18, 0.35, 0.7 and 1.1 mg |
| Prasugrel Base | Prophylaxis and therapy of thrombosis | Film-coated tablets | 5 and 10 mg |
| Pregabaline * | Neuropathic pain | Tablets | 25, 50, 75, 100, 150, 200, 225 and 300 mg |
| Promethazine | Agitation and restlessness | Injection | 25mg/ ml |
| Promethazine | Agitation and restlessness | Oral solution | 20mg/ ml 100mg/ ml |
| Quetiapine * | Psychosis, schizophrenia, bipolar disoder | Film-coated tablets | 25, 50, 100, 150, 200, 300 and 400 mg |
| Quetidia® | Useful for the management of anxiety disorders | Sep 2014 | |
| Quetidia® oral solution | Useful for the management of anxiety disorders | Sep 2017 | |
| Rasagiline (tartrate) | Parkinson's | Tablets | 1 mg |
| Risperidone | Psychosis, schizophrenia, bipolar disoder | Film-coated tablets | 1, 3 and 6 mg |
| Rivaroxaban | Thrombosis, stroke | Film-coated tablets | 10, 15 and 20 mg |
| Rizatriptan | Migraine | Orodispersable tablets | 5 and 10 mg |
| Seripnol® | Useful to promote relaxation and sleep | Mar 2012 | |
| Seripnol® drops | Useful to promote relaxation and sleep | Apr 2014 |
|
| Sodium Oxybate | Narcolepsy | Oral solution | 500 mg/ml |
| Solifenacin | Overactive bladder, urinary incontinence | Film-coated tablets | 5 and 10 mg |
| Sulpiride | Psychosis, schizophrenia | Tablets | 50 and 200 mg |
| Sultiame * | Epilepsy, convulsions | Film-coated tablets | 50, 100 and 200 mg |
[*] Differentiated product
[**] Opioid
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.